Other languages Compass Therapeutics, Inc.

Equities

CMPX

US20454B1044

Delayed Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
1.47 ^USD	-1.67%		-8.12%	-5.77%

May. 23	Compass Therapeutics to Present Phase 1 Data for CTX-471, a Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology Annual Meeting 2024	CI
May. 13	Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Compass Therapeutics to Present Phase 1 Data for CTX-471, a Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology Annual Meeting 2024	May. 23
Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13
Top Premarket Gainers	May. 06
Compass Therapeutics Gets FDA Fast-Track Designation for Biliary Tract Cancer Treatment	Apr. 25
Compass Therapeutics, Inc. Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated	Apr. 25
Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors	Apr. 16
Compass Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21
Compass Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21
Compass Therapeutics Reports Positive Result in Lung Cancer Treatment Trial -- Shares Rise	Jan. 05
Compass Therapeutics, Inc. Announces Executive Changes, Effective January 9, 2024	Jan. 05
Compass Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 9, 2024	Jan. 05
Compass Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Ankyra Therapeutics Names Robert V. Tighe as Chief Scientific Officer	23-08-15
Compass Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03
Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04
Compass Therapeutics, Inc. Appoints Richard S. Lindahl as Class III Director, Member and Chairman of the Audit Committee	23-04-24
Compass Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-15
Compass Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-15
Compass Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15
Compass Therapeutics, Inc. Announces Resignation of David Wurzer to Board of Directors and Committees	23-02-24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Compass Therapeutics, Inc.

Equities

CMPX

US20454B1044

Other languages

Filters